Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Welcome and Introduction to Vi3C

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Mar
26
Today In Oncology
AI As Collaborator in Cancer Research and in Clinical Care
AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?
Neoadjuvant GOLP in High-Risk Intrahepatic Cholangiocarcinoma
Gedatolisib-Based Regimens in HR-Positive HER2-Negative PIK3CA Wild-Type Advanced Breast Cancer
Hyperplasia and the Link Between Obesity and Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo